Hyperbaric oxygen therapy for acute coronary syndrome
Authors:
- Michael H BennettMBMichael H Bennett
- Jan P LehmJLJan P Lehm
- Nigel JepsonNJNigel Jepson
- 20 April 2005
- reference entry
- Published by Wiley
- No. 2,p. CD004818
Abstract
Acute coronary syndrome (ACS) includes acute myocardial infarction and unstable angina. ACS is common and may prove fatal. Hyperbaric oxygen therapy (HBOT) will improve oxygen supply to the threatened heart and may reduce the volume of heart muscle that will perish. The addition of HBOT to the standard treatment may reduce death rate and other major adverse outcomes. To assess the benefits and harms of adjunctive HBOT for treating ACS. We searched the following from inception to November 2004: CENTRAL, MEDLINE, EMBASE, CINAHL, DORCTHIM, and references from selected articles. Relevant journals were handsearched and researchers in the field contacted. Randomised studies comparing the effect on ACS of regimens that include HBOT with those that exclude HBOT. Three reviewers independently evaluated the quality of trials using the guidelines of the Cochrane Handbook and extracted data from included trials. Four trials with 462 participants contributed to this review. There was a trend towards, but no significant decrease in, the risk of death with HBOT (relative risk (RR) 0.64, 95% CI 0.38 to 1.06, P=0.08). There was evidence from individual trials of reductions in the risk of major adverse coronary events [MACE] (RR 0.12, 95% CI 0.02 to 0.85, P=0.03; NNT 4, 95% CI 3 to 10) and some dysrhythmias following HBOT (RR 0.59, 95% CI 0.39 to 0.89, P=0.01; NNT 6, 95% CI 3 to 24), particularly complete heart block (RR 0.32, 95%CI 0.12 to 0.84, P=0.02), and that the time to relief of pain was reduced with HBOT (Weighted Mean Difference [WMD] 353 minutes shorter, 95% CI 219 to 488, P<0.0001). One trial suggested a significant incidence of claustrophobia in single occupancy chambers of 15% (RR of claustrophobia with HBOT 31.6, 95%CI 1.92 to 521, P=0.02). For people with ACS, individual small trials suggest the addition of HBOT reduced the risk of Major Adverse Cardiac Events, some dysrrhythmias, and reduced the time to relief from ischaemic pain, but did not reduce mortality. In view of the modest number of patients, methodological shortcomings and poor reporting, this result should be interpreted cautiously, and an appropriately powered trial of high methodological rigour is justified to define those patients (if any) who can be expected to derive most benefit from HBOT. The routine application of HBOT to these patients cannot be justified from this review.Keywords
This publication has 22 references indexed in Scilit:
- Adjunctive effect of hyperbaric oxygen treatment after thrombolysis on left ventricular function in patients with acute myocardial infarctionAmerican Heart Journal, 2004
- Hyperbaric oxygen treatment does not affect left ventricular chamber stiffness after myocardial infarction treated with thrombolysisAmerican Heart Journal, 2004
- Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectorisThe American Journal of Cardiology, 2004
- From Vulnerable Plaque to Vulnerable PatientCirculation, 2003
- Induction of heme oxygenase-1 and adaptive protection against the induction of DNA damage after hyperbaric oxygen treatmentCarcinogenesis, 2000
- Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction: The ‘HOT MI’ Randomized Multicenter StudyCardiology, 1998
- Hyperbaric oxygen and thrombolysis in myocardial infarction: The "HOT MI" Pilot studyAmerican Heart Journal, 1997
- Oxygen-dependent antagonism of lipid peroxidationFree Radical Biology and Medicine, 1991
- Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activatorAmerican Heart Journal, 1990
- Severe acute myocardial infarction treated with hyperbaric oxygen. Report on forty patientsPostgraduate Medical Journal, 1969